58743-80-9

Basic information

• Product Name: 1-(4-Bromophenyl)-4-ethoxybenzene
• Synonyms: 1-(4-Bromophenyl)-4-ethoxybenzene;4-Bromo-4'-ethoxybiphenyl
• CAS NO: 58743-80-9
• Molecular Formula: C₁₄H₁₃BrO
• Molecular Weight: 277.15642
• Mol File: 58743-80-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Bromophenyl)-4-ethoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Bromophenyl)-4-ethoxybenzene(58743-80-9)
• EPA Substance Registry System: 1-(4-Bromophenyl)-4-ethoxybenzene(58743-80-9)

Safety Data

• Hazardous Substances Data: 58743-80-9(Hazardous Substances Data)

Usage

General Description

1-(4-Bromophenyl)-4-ethoxybenzene is a chemical compound with the molecular formula C14H13BrO. It is a derivative of benzene with a bromine atom and an ethoxy group attached to the phenyl ring. The compound is a white to off-white solid with a molecular weight of 259.16 g/mol. It is often used as a building block in organic synthesis and can be found in various research and industrial applications. Its properties and structure make it useful in the production of pharmaceuticals, agrochemicals, and materials. Due to its potential reactivity and toxicity, proper handling and storage procedures should be followed when working with 1-(4-Bromophenyl)-4-ethoxybenzene.

Upstream product

• 64-67-5 diethyl sulfate 
• 29558-77-8 4-bromo-4'-hydroxybiphenyl 
• 589-87-7 1,4-bromoiodobenzene 
• 22237-13-4 (4-ethoxyphenyl)boronic acid 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 
• 584-08-7 potassium carbonate 

Downstream Products

• 182344-29-2 4'-ethoxybiphenyl-4-yl boronic acid 
• 1192136-38-1 (S)-((3aS,5S,6R,6aS)-6-(tert-butyldimethylsilyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(4'-ethoxybiphenyl-4-yl)methanol 
• 58743-78-5 4'-ethoxybiphenyl-4-carbonitrile 

Relevant articles and documents

C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents

A series of highly active C-aryl glucoside SGLT2 inhibitors containing a biphenyl motif were designed and synthesized for biological evaluation. Among the compounds tested, compound 16l demonstrated high inhibitory activity against SGLT2 (IC50 = 1.9 nM) with an excellent pharmacokinetic profile. Further study indicated that the in vivo efficacy of compound 16l was comparable to that of dapagliflozin, suggesting that further development would be worthwhile.

SUBSTITUTED CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula STR1 wherein each T is a substituent g roup; x is 0, 1, or 2; the group D represents STR2 the subscript "e" is 2 or 3; the group R 14 represents a variety of possible substituent groups of the cycloalkyl ring between D and G; the subscript "k" is 0-2; and the group G represents M, STR3 in which M represents--CO 2 H,--CON(R 11) 2, or--CO 2 R 12 ; and R 13 represents any of the side chains of the 19 noncyclic occurring amino acids. "